End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5,100 MXN | +3.92% | -.--% | -4.52% |
05-21 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
05-21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
Sales 2024 * | 19.8B 2.88B 48.27B 3.93B | Sales 2025 * | 23.62B 3.43B 57.58B 4.69B | Capitalization | 125B 18.14B 304B 24.78B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 680M 11.39B 928M | Net income 2025 * | 6.61B 962M 16.12B 1.31B | EV / Sales 2024 * | 4.99 x |
Net cash position 2024 * | 25.9B 3.77B 63.15B 5.14B | Net cash position 2025 * | 32.35B 4.71B 78.87B 6.43B | EV / Sales 2025 * | 3.91 x |
P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.4
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | +3.92% | ||
3 months | +3.92% | ||
6 months | -4.26% | ||
Current year | -4.52% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.08% | 21.83B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B | |
-30.73% | 7.6B |
- Stock Market
- Equities
- GMAB Stock
- GMAB N Stock